DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma?

Ann Oncol. 2012 Sep;23(9):2211-2214. doi: 10.1093/annonc/mds157. Epub 2012 Jun 8.

Authors

E Felip¹, A Martinez-Marti²

Affiliations

¹ Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: efelip@vhebron.net.
² Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

PMID: 22684743
DOI: 10.1093/annonc/mds157

No abstract available

Publication types

Editorial

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / metabolism*
Adenocarcinoma / surgery
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / metabolism*
Carcinoma, Non-Small-Cell Lung / surgery
Carcinoma, Squamous Cell / drug therapy
Carcinoma, Squamous Cell / metabolism*
Carcinoma, Squamous Cell / surgery
Cisplatin / administration & dosage
Clinical Trials as Topic
DNA Repair
DNA Repair Enzymes / genetics
DNA Repair Enzymes / metabolism*
Drug Resistance, Neoplasm
Gene Expression
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / metabolism*
Lung Neoplasms / surgery
Treatment Outcome

Substances

DNA Repair Enzymes
Cisplatin